| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Constantinos M Mikelis | |
| George Mattheolabakis | |||
| P2860 | cites work | The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2 | Q24608778 |
| The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2 | Q24646996 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 | Q27861068 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Molecular mechanisms and clinical applications of angiogenesis | Q29547314 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| Nanocarriers as an emerging platform for cancer therapy | Q29616699 | ||
| Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. | Q30358121 | ||
| Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia | Q30399006 | ||
| Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. | Q30443689 | ||
| Solid lipid nanoparticles: a modern formulation approach in drug delivery system | Q30481400 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial-mesenchymal transition inhibition | Q33650400 | ||
| Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer | Q33656658 | ||
| Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions | Q33770680 | ||
| Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine | Q33866374 | ||
| Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. | Q50951676 | ||
| Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes. | Q53006384 | ||
| Non-Viral Based miR Delivery and Recent Developments. | Q54231141 | ||
| Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Q55190117 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma | Q56889461 | ||
| Emerging applications of upconverting nanoparticles in intestinal infection and colorectal cancer | Q64235025 | ||
| Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery | Q64239906 | ||
| Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting | Q83165400 | ||
| Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals | Q86291066 | ||
| Delivery of small interfering RNA against Nogo-B receptor via tumor-acidity responsive nanoparticles for tumor vessel normalization and metastasis suppression | Q88873222 | ||
| Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer | Q89361908 | ||
| Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment | Q91051056 | ||
| Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines | Q91069512 | ||
| Targeted Nanodelivery of Drugs and Diagnostics | Q33900258 | ||
| Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. | Q34447986 | ||
| To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? | Q34545282 | ||
| Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells | Q34984247 | ||
| Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner | Q36016318 | ||
| Nanoliposomal Nitroglycerin Exerts Potent Anti-Inflammatory Effects. | Q36301173 | ||
| Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. | Q36770262 | ||
| OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer | Q36822179 | ||
| Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles | Q36833069 | ||
| Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy | Q37137190 | ||
| Principles of nanoparticle design for overcoming biological barriers to drug delivery | Q37162182 | ||
| Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. | Q37340643 | ||
| Exploiting macrophages as targeted carrier to guide nanoparticles into glioma | Q37392913 | ||
| Tumour angiogenesis regulation by the miR-200 family | Q37523569 | ||
| Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy | Q37641818 | ||
| Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. | Q37662252 | ||
| Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. | Q37696695 | ||
| Nivolumab in renal cell carcinoma: latest evidence and clinical potential | Q37698611 | ||
| Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. | Q37871679 | ||
| Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases | Q37883025 | ||
| Doxil®--the first FDA-approved nano-drug: lessons learned | Q38000876 | ||
| Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives | Q38059498 | ||
| The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies | Q38183889 | ||
| Pembrolizumab: first global approval | Q38261580 | ||
| Monitoring immune-checkpoint blockade: response evaluation and biomarker development | Q38666241 | ||
| Actively Targeted Nanoparticles for Drug Delivery to Tumor | Q38849488 | ||
| Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment | Q39003100 | ||
| Tumor angiogenesis and vascular normalization: alternative therapeutic targets | Q39403862 | ||
| Liposome: classification, preparation, and applications | Q41049173 | ||
| Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice. | Q41565207 | ||
| The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms | Q41577994 | ||
| Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model | Q42573981 | ||
| Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. | Q42708321 | ||
| Toxicity of a soybean oil emulsion on human lymphocytes and neutrophils | Q46976057 | ||
| Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys | Q47175243 | ||
| Normalizing Tumor Vessels To Increase the Enzyme-Induced Retention and Targeting of Gold Nanoparticle for Breast Cancer Imaging and Treatment. | Q48168833 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | nanoparticle | Q61231 |
| P304 | page(s) | 1227 | |
| P577 | publication date | 2019-11-12 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg? | |
| P478 | volume | 9 |
Search more.